Conformetrix to discuss partnering at BioCap 2012

Conference to highlight vibrant life sciences sector in Northern England

Manchester, UK, November 5 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will take part in a panel discussion on big pharma partnering at BioCap 20121 in Manchester on November 6 2012.

The BioNow conference, bringing together international investors and high quality companies, will highlight the wealth of life sciences expertise across industry and academia in Northern England.

On the panel, CEO Dr Sam Williams will share his insights into optimal partnering strategies as well as thoughts on current trends. Conformetrix is a spin-out from the University of Manchester, working with companies across the sector to optimise drug discovery and design.

Conformetrix’s NMR technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programmes.

1 BioCap 2012 - the North of England Life Science Investment and Showcase Conference, November 6 2012, Manchester, UK. BioCap 2012 Event Page